Diagnostics life sciences company Amplified Sciences has announced the launch of PanAMP, a real-world, multicenter study to assess the impact of its PanCystPro assay on healthcare providers’ patient management decisions. (Purdue Research Foundation photo/Jennifer Mayberry)
May 8, 2026 | Steve Martin
WEST LAFAYETTE, Ind. — Amplified Sciences, a diagnostics life sciences company revolutionizing early disease detection, announced Friday (May 8) the launch of PanAMP, a clinical utility study for its PanCystPro assay.
This real-world, multicenter study in patients with radiographically confirmed pancreatic cysts aims to assess the impact of the company’s PanCystPro assay on healthcare providers’ patient management decisions.
Amplified Sciences CEO Diana Caldwell said PanCystPro helps risk-stratify patients with a known precursor for pancreatic cancer — those diagnosed with pancreatic cystic lesions, which represent a window to earlier detection of the cancer.
“These cystic lesions are a challenge for many clinicians, and the use of innovative tests like PanCystPro alongside imaging can provide insights on surveillance and treatment strategies for those patients at higher risk for pancreatic cancer,” Caldwell said.
Principal investigators of the PanAMP study are:
- Dr. Mohammad Al-Haddad, Indiana University School of Medicine, Indianapolis
- Dr. Srinivas Gaddam, Cedars-Sinai Medical Center, Los Angeles
- Dr. Mandeep Sawhney, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston
- Dr. Arvind Trindade, Rutgers Health and RWJBarnabas Health, New Brunswick, New Jersey
“Pancreatic cystic lesion management remains one of the most challenging areas in our daily practice due to persistent diagnostic uncertainty,” Al-Haddad said. “Incorporating an accurate low-volume test like PanCystPro into the diagnostics workflow has the potential to provide clinicians with more actionable information to determine surveillance frequency and treatment strategies.”
Amplified Sciences and Purdue University
Purdue University researcher V. Jo Davisson and CEO Diana Caldwell are the founders of Amplified Sciences, a life sciences diagnostic company. (Purdue Research Foundation photo/Jennifer Mayberry)
He disclosed the intellectual property through the Purdue Innovates Office of Technology Commercialization. OTC executed an exclusive license with Amplified Sciences for the global suite of patents.
Amplified Sciences is a Purdue Innovates Ventures portfolio company. Ventures most recently supported Amplified Sciences with an investment in the company’s $2.6 million Series Seed Preferred capital raise in 2023.
About Amplified Sciences
Amplified Sciences is a life science diagnostics company focused on providing innovative diagnostic tests that enable earlier detection, risk stratification and monitoring of serious diseases. BioMatra™, the company’s ultrasensitive optical reporter platform, leverages technology licensed from Purdue University. Its headquarters is in West Lafayette, Indiana, and the CLIA-CAP accredited clinical lab is located in Irvine, California. To learn more about Amplified Sciences, visit amplifiedsciences.com.
About Purdue Innovates Office of Technology Commercialization
The Purdue Innovates Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university’s academic activities through commercializing, licensing and protecting Purdue intellectual property. In fiscal year 2025, the office reported 161 deals executed with 269 technologies licensed, 479 invention disclosures received, and 267 U.S. and international patents received. The office is managed by the Purdue Research Foundation, a private, nonprofit foundation created to advance the mission of Purdue University. Contact otcip@prf.org for more information.
About Purdue University
Purdue University is a public research university leading with excellence at scale. Ranked among top 10 public universities in the United States, Purdue discovers, disseminates and deploys knowledge with a quality and at a scale second to none. More than 106,000 students study at Purdue across multiple campuses, locations and modalities, including more than 57,000 at our main campus locations in West Lafayette and Indianapolis. Committed to affordability and accessibility, Purdue’s main campus has frozen tuition 14 years in a row. See how Purdue never stops in the persistent pursuit of the next giant leap — including its integrated, comprehensive Indianapolis urban expansion; the Mitch Daniels School of Business; Purdue Computes; and the One Health initiative — at https://www.purdue.edu/president/strategic-initiatives.
Media contacts: Diana Caldwell, diana.caldwell@amplifiedsci.com; Steve Martin, sgmartin@prf.org
